Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Access Microbiology

Rezafungin for sternal wound infection caused by multidrug-resistant Candidozyma auris: a case report

  1. 1University Hospital Southampton National Health Service Foundation Trust, Southampton, UK

Abstract

Introduction. Candidozyma auris is an emerging multidrug-resistant fungal pathogen associated with healthcare outbreaks and significant mortality. Management can be challenging due to antifungal resistance and the need for prolonged intravenous therapy.

Case Presentation. A 58-year-old man developed a postoperative sternal wound infection caused by multidrug-resistant C. auris following aortic valve replacement, coronary artery bypass grafting and ascending aortic interposition graft surgery. His postoperative course was complicated by Staphylococcus epidermidis prosthetic graft infection requiring redo valve replacement and graft repair and placement of vacuum-assisted closure. Two weeks after discharge home, persistent wound discharge yielded C. auris. Following surgical debridement and initiation of intravenous caspofungin with oral itraconazole, once-daily intravenous antifungal therapy was transitioned to once-weekly intravenous rezafungin to facilitate outpatient treatment coordinated with vacuum-assisted wound therapy.

Conclusion. After 12 weeks of dual antifungal therapy, complete clinical and microbiological resolution was achieved without adverse events. This case highlights the feasibility of rezafungin as an outpatient treatment strategy for complex multidrug-resistant C. auris infections.

Related

  1. Candidozyma auris (formerly Candida auris): A P6 medicine framework integrating genomics, surveillance and the prevention of multidrug-resistant fungal threats.
    Styliani Geronikolou, George P Chrousos
    Medicine internationalPeer-reviewedCC BYFull textInfectious diseaseEurope PMC
  2. Immune dysregulation: an “accelerator” of gut resistome expansion and multidrug-resistant organism infection risk in ICU patients
    Rujie Xu, Feimeisi Zhou, Kaihuai Wu +3
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineCrossrefDOAJFrontiers
  3. A High-Energy Military Femoral Fracture With Multidrug-Resistant Infection: A Case Report.
    Andris Vikmanis, Olegs Ribakovs, Anete Labalaika
    The American journal of case reportsPeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMC
  4. Probable primary bloodstream infection caused by multidrug-resistant Achromobacter piechaudii in an apparently immunocompetent child: a case report
    Yunfeng Xiang, Ling Duan, Daoxue Xiong +1
    BMC PediatricsPeer-reviewedCC BY 4.0Full text1 citedInfectious diseasePMC
  5. Case Report: Herbal nutritional intervention in a critically ill ALS patient with multidrug-resistant infection.
    Meng Wang, Chihim Mak, Xinjie Li +13
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{luthra2026rezafungin,
  title = {{Rezafungin for sternal wound infection caused by multidrug-resistant Candidozyma auris: a case report}},
  author = {Suvitesh Luthra and Annette David and David Thirukumaran and Tat Shing Yam},
  journal = {Access Microbiology},
  year = {2026},
  month = nov,
  doi = {10.1099/acmi.0.001171.v4},
  url = {https://doi.org/10.1099/acmi.0.001171.v4},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Rezafungin for sternal wound infection caused by multidrug-resistant Candidozyma auris: a case report
AU  - Suvitesh Luthra
AU  - Annette David
AU  - David Thirukumaran
AU  - Tat Shing Yam
PY  - 2026
DA  - 2026/11/12
JO  - Access Microbiology
DO  - 10.1099/acmi.0.001171.v4
UR  - https://doi.org/10.1099/acmi.0.001171.v4
AB  - Introduction. Candidozyma auris is an emerging multidrug-resistant fungal pathogen associated with healthcare outbreaks and significant mortality. Management can be challenging due to antifungal resistance and the need for prolonged intravenous therapy.  Case Presentation. A 58-year-old man developed a postoperative sternal wound infection caused by multidrug-resistant C. auris following aortic valve replacement, coronary artery bypass grafting and ascending aortic interposition graft surgery. His postoperative course was complicated by Staphylococcus epidermidis prosthetic graft infection requiring redo valve replacement and graft repair and placement of vacuum-assisted closure. Two weeks after discharge home, persistent wound discharge yielded C. auris. Following surgical debridement and initiation of intravenous caspofungin with oral itraconazole, once-daily intravenous antifungal therapy was transitioned to once-weekly intravenous rezafungin to facilitate outpatient treatment coordinated with vacuum-assisted wound therapy.  Conclusion. After 12 weeks of dual antifungal therapy, complete clinical and microbiological resolution was achieved without adverse events. This case highlights the feasibility of rezafungin as an outpatient treatment strategy for complex multidrug-resistant C. auris infections.
SN  - 2516-8290
ER  -